Pipeline
| Description | Tropism | Payload(s) | Stage | |
|
GVB2040 |
Cancer vaccine |
Tumor, DCs |
Immuno-stimulating gene, transcription factor (+/- tumor associated antigens) |
Preclinical: cell line data |
|
GVB2030 (lead program) |
Oncolytic vaccinia virus in combination of anti-PD-1 against bladder cancer |
Tumor, tumor associated vasculature |
Cytokines |
Preclinical: cell and animal data |
|
GVB2020 |
In vivo transduction vector for CAR- or TCR-T cells (oncology & immunology) |
T-Cells |
Cytokines and CAR- or TCR-construct |
Preclinical: validated in cells |
|
GVB2010 |
Oncolytic vaccinia virus for systematic delivery |
Tumor, Tumor associated vasculature |
Immunogenic cell death, checkpoint inhibitor, fusogenic |
Preclinical: validated in animal models |
Subscribe to our emails
Stay up to date on Genvira Biosciences